Literature DB >> 7987972

Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

V Pinzani1, F Bressolle, I J Haug, M Galtier, J P Blayac, P Balmès.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7987972     DOI： 10.1007/BF00686277

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  84 in total

1.  Clinical trials of WR-2721 and cis-platinum.

Authors:  D Glover; S Grabelsky; K Fox; C Weiler; L Cannon; J Glick
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-05       Impact factor: 7.038

2.  Cis-diamminedichloroplatinum (NSC-119875): a phase I study.

Authors:  D J Higby; H J Wallace; J F Holland
Journal:  Cancer Chemother Rep       Date:  1973 Nov-Dec

3.  Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.

Authors:  D L Bodenner; P C Dedon; P C Keng; J C Katz; R F Borch
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

4.  Renal tubular function in patients treated with high-dose cisplatin.

Authors:  G Daugaard; U Abildgaard; N H Holstein-Rathlou; I Bruunshuus; D Bucher; P P Leyssac
Journal:  Clin Pharmacol Ther       Date:  1988-08       Impact factor: 6.875

5.  Modification of cisplatin toxicity with diethyldithiocarbamate.

Authors:  J M Berry; C Jacobs; B Sikic; J Halsey; R F Borch
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

6.  Urinastatin (Kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity.

Authors:  S Umeki; K Tsukiyama; N Okimoto; R Soejima
Journal:  Am J Med Sci       Date:  1989-10       Impact factor: 2.378

7.  Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity.

Authors:  P Salem; M Khalyl; K Jabboury; L Hashimi
Journal:  Cancer       Date:  1984-02-15       Impact factor: 6.860

8.  Protective effect of organic cation transport inhibitors on cis-diamminedichloroplatinum-induced nephrotoxicity.

Authors:  J E Bird; M M Walser; A J Quebbemann
Journal:  J Pharmacol Exp Ther       Date:  1984-12       Impact factor: 4.030

9.  Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

Authors:  G Daugaard; N Rossing; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug.

Authors:  P M Calabro-Jones; J A Aguilera; J F Ward; G D Smoluk; R C Fahey
Journal:  Cancer Res       Date:  1988-07-01       Impact factor: 12.701
View more
  28 in total

1.  Synthesis, characterization, and photophysical properties of three platinum(II) complexes bearing fluorescent analogues of the Di-2-pyridylmethane ligand.

Authors:  Justin J Wilson; Juliana Fedoce Lopes; Stephen J Lippard
Journal:  Inorg Chem       Date:  2010-06-07       Impact factor: 5.165

Review 2.  Renal toxicity and chemotherapy in children with cancer.

Authors:  Antonio Ruggiero; Pietro Ferrara; Giorgio Attinà; Daniela Rizzo; Riccardo Riccardi
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

3.  Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin.

Authors:  M H Hanigan; E D Lykissa; D M Townsend; C N Ou; R Barrios; M W Lieberman
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

4.  Effect of combined treatment with micelle-incorporated cisplatin (NC-6004) and S-1 on human gastric cancer xenografts.

Authors:  Masahisa Kudo; Yoshiyuki Yamamoto; Yoshikatsu Koga; Tetsuya Hamaguchi; Tetsuo Akimoto; Masahiro Yasunaga; Yasuhiro Matsumura
Journal:  Mol Clin Oncol       Date:  2016-11-01

5.  Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system.

Authors:  N Nishiyama; Y Kato; Y Sugiyama; K Kataoka
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

Review 6.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.

Authors:  Darren Lars Stirland; Joseph W Nichols; Seiji Miura; You Han Bae
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

7.  Self-assembling peptide amphiphile-based nanofiber gel for bioresponsive cisplatin delivery.

Authors:  Jin-Ki Kim; Joel Anderson; Ho-Wook Jun; Michael A Repka; Seongbong Jo
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

Review 8.  Renal function following hematological stem cell transplantation in childhood.

Authors:  Ludwig Patzer; Karim Kentouche; Felix Ringelmann; Joachim Misselwitz
Journal:  Pediatr Nephrol       Date:  2003-04-29       Impact factor: 3.714

9.  Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma.

Authors:  Kazuhira Endo; Takayoshi Ueno; Satoru Kondo; Naohiro Wakisaka; Shigeyuki Murono; Makoto Ito; Kazunori Kataoka; Yasuki Kato; Tomokazu Yoshizaki
Journal:  Cancer Sci       Date:  2013-01-30       Impact factor: 6.716

10.  Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients.

Authors:  F E de Jongh; R N van Veen; S J Veltman; R de Wit; M E L van der Burg; M J van den Bent; A S Th Planting; W J Graveland; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.